Fusion Protein Immune Modulation via Segmented Domain Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating immune responses are limited in effectively enhancing or repressing antigen-specific immunity, particularly in treating chronic diseases such as cancer, infectious diseases, autoimmune diseases, allergies, and inflammatory diseases, with existing immunotherapies often having non-specific effects and significant side effects.
Innovation Solution
Development of nucleic acid constructs encoding soluble fusion proteins that combine co-stimulation ligands with Fas death receptor ligands and immunoglobulin Fc domains, which, when administered, elicit enhanced or repressed immune responses by stimulating specific immune cells, such as T cells and B cells, to induce cell proliferation, cytokine production, or immunoglobulin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapy methods are used to modulate immune responses, then immune responses can be affected, but the effects are non-specific and cause significant side effects
Solution Approach 1:
The patent segments the immune modulation function into multiple distinct fusion proteins, each targeting specific immune cell receptors (CD3, CD28, CD40, Fas). Instead of using broad non-specific immunotherapies, the invention creates specialized agents that can be selected and combined based on the desired immune response (enhancement or repression), thereby improving specificity and reducing off-target side effects.
Solution Approach 2:
The patent applies local quality by designing fusion proteins with specific functional domains tailored to target particular immune cell types and pathways. Each fusion protein contains specific ligand domains (e.g., CD3ε, CD28, CD40, Fas) that bind to corresponding receptors on specific immune cells, enabling localized and targeted immune modulation rather than global non-specific effects.
2Reliability
If existing immunotherapies are administered to treat chronic diseases, then some immune response modulation is achieved, but therapeutic efficacy is limited and side effects are significant
Solution Approach 1:
The patent employs composite materials by creating fusion proteins that combine multiple functional domains within single molecular structures. These fusion proteins integrate antigen recognition, costimulation, and cytotoxic or regulatory functions into unified therapeutic agents, enabling multi-functional immune modulation that enhances therapeutic efficacy while maintaining safety through targeted action.
3Productivity
If broad immune activation is used to enhance antigen-specific immunity, then immune response magnitude increases, but specificity decreases and harmful effects increase
Solution Approach 1:
The patent applies dynamics by providing a flexible system where fusion proteins can be dynamically selected and combined based on therapeutic needs. The invention enables clinicians to choose specific fusion protein combinations (e.g., enhancing vs. repressing agents) and adjust dosing regimens to achieve the desired balance between immune response magnitude and specificity for each patient and disease condition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The soluble fusion proteins significantly enhance or repress antigen-specific immune responses, providing a targeted approach to treat various chronic diseases by activating or inhibiting immune cells as needed, offering improved therapeutic efficacy with reduced side effects.
Implementation Method 1
The soluble fusion proteins significantly enhance or repress antigen-specific immune responses by activating or inhibiting immune cells
Data Source
AI summary
The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.